Fox Chase Chemical Diversity Center Inc (FCCDC) specializes in medicinal chemistry, understanding the relation of structure to function in biomedical research, early stage drug discovery, probe library synthesis and target validation for academic and biotechnology company partners. Fully-equipped to make libraries of new chemical entities, equipment infrastructure includes NMR, microwave, serial HPLC, LC/MS and Genovac technologies. Extensive experience in the major pharmaceutical industry employing modern methods of medicinal chemistry and structure based drug desigis focused on providing medicinal chemistry/chemical biology support to basic research programs. The goal is to assist researchers to develop their fundamental research into bona fide drug discovery programs. The company does this through a variety of means: 1. Seek, find and develop molecular probes to better elucidate their target and potential therapeutic application. 2. Advance Hits from screening to Lead status, using in silico design and chemical synthesis via small directed libraries or individual compounds; improve/develop structural activity relationships (SAR) as well as evaluate/improve ADME properties. 3. Determine the Intellectual Property position of the chemical matter and provide a path forward for which novel compositions can be made and protected. At FCCDC, The firm has over 60 years of industrial experience ranging from big pharma (J&J, Merck), biotech and contract research organizations. Partial list of therapeutic areas and target classes studied: * Central nervous system, neurology and psychiatry, * Anti-infectives (antibacterial and antiviral), * Inflammation and immunology, * Diabetes and obesity, multiple targets, * Ion channels (IKr, Iks, nAChRs), * GPCRs (integrins, avb3, 5-HT, dopamine, adrenergic), * Kinases (Raf, p38, DAPK)
